2. Search Result
Search Result
Isoforms Recommended: HIPK
Results for "

HIPK2

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100464
    tBID
    Maximum Cited Publications
    6 Publications Verification

    		 DYRK Cancer
    tBID is a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2) with an IC50 of 0.33 μM.
    tBID
  • HY-128439
    BT173

    		DYRK Cancer
    BT173 is a potent homeodomain interacting protein kinase 2 (HIPK2) inhibitor. BT173 binds to HIPK2 and does not inhibit HIPK2 kinase activity but rather, interfered allosterically with the ability of HIPK2 to associate with Smad3. BT173 attenuates renal fibrosis through suppression of the TGF-β1/Smad3 pathway. BT173 can be studied in research for kidney diseases such as renal fibrosis .
    BT173
  • HY-U00439A
    Protein kinase inhibitor 1 hydrochloride
    4 Publications Verification

    		 DYRK Cancer
    Protein kinase inhibitor 1 hydrochloride is a potent HIPK2 inhibitor, with IC50s of 136 and 74 nM for HIPK1 and HIPK2, and a Kd of 9.5 nM for HIPK2.
    Protein kinase inhibitor 1 hydrochloride
  • HY-135906
    CK2/ERK8-IN-1
    2 Publications Verification

    		 Casein Kinase ERK Pim DYRK Apoptosis Cancer
    CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy .
    CK2/ERK8-IN-1
  • HY-E70830
    HIPK2 Recombinant Human Active Protein Kinase

    		DYRK Cancer
    Homeodomain interacting protein kinase 2 (HIPK2) is an evolutionary conserved serine/threonine kinase that regulates gene expression by phosphorylation of transcription factors and accessory components of the transcription machinery. HIPK2 is activated in response to DNA-damaging agents or morphogenic signals. HIPK2 Recombinant Human Active Protein Kinase is a recombinant HIPK2 protein that can be used to study HIPK2-related functions .
    HIPK2 Recombinant Human Active Protein Kinase
  • HY-177416
    MU1787

    		DYRK Cancer
    MU1787 is a highly selective homeodomain-interacting protein kinase (HIPK) inhibitor with a furopyridine core, and shows improved selectivity against CLKs, with inactivity against DYRK1B, DYRK2, and MLK2/3 in in vitro cellular assays. MU1787 can be used for the research of malignancies .
    MU1787
  • HY-RS23297
    Hipk2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) DYRK Others

    Hipk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hipk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    Hipk2 siRNA-1: 5 nmol (HPLC)

    Hipk2 siRNA-2: 5 nmol (HPLC)

    Hipk2 siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)
    Hipk2 Rat Pre-designed siRNA Set A
    Hipk2 Rat Pre-designed siRNA Set A
  • HY-RS06182
    HIPK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HIPK2 Human Pre-designed siRNA Set A contains three designed siRNAs for HIPK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HIPK2 Human Pre-designed siRNA Set A
    HIPK2 Human Pre-designed siRNA Set A
  • HY-RS16856
    Hipk2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Hipk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hipk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hipk2 Mouse Pre-designed siRNA Set A
    Hipk2 Mouse Pre-designed siRNA Set A
  • HY-U00439
    Protein kinase inhibitor 1

    		DYRK Cancer
    Protein kinase inhibitor 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
    Protein kinase inhibitor 1
  • HY-179378
    XRF-1021

    		DYRK TGF-beta/Smad NF-κB Wnt β-catenin MDM-2/p53 Notch Inflammation/Immunology
    XRF-1021 is an orally active HIPK2 inhibitor (IC50 = 0.18 μM). XRF-1021 reduces the expression of fibrotic markers in TGF-β1 stimulated NRK-49F and HK-2 cells, including Fibronectin, Collagen I and α-SMA. XRF-1021 blocks TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch signaling. XRF-1021 reduces renal injury and fibrosis in vivo. XRF-1021 can be used for the research of chronic kidney disease .
    XRF-1021
  • HY-100464R
    tBID (Standard)

    		DYRK Reference Standards Cancer
    tBID (Standard) is the analytical standard of tBID (HY-100464). This product is intended for research and analytical applications. tBID is a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2) with an IC50 of 0.33 μM.
    tBID (Standard)
  • HY-W152736
    2-Methyl-5-acetylphenol

    		DYRK Neurological Disease
    2-Methyl-5-acetylphenol is a hydroxylated methylacetophenone that exists in the aerial parts of Cannabis sativa subsp. sativa. 2-Methyl-5-acetylphenol exhibits strong binding affinity to HIPK2. 2-Methyl-5-acetylphenol cannot reverse MPP + (1-methyl-4-phenyl-pyridinium ion)-induced neuronal cytotoxicity. 2-Methyl-5-acetylphenol can be used for Parkinson's disease research .
    2-Methyl-5-acetylphenol
  • HY-122670
    VS-II-173

    		Pim Apoptosis AMPK DYRK STAT MDM-2/p53 Cancer
    VS-II-173 is a pan-Pim kinase inhibitor with IC50 values ​​of 0.07 μM and 0.02 μM for Pim1 and Pim3, respectively, and a residual activity of 46% for Pim2 at 1 μM. VS-II-173 also inhibits kinases such as HIPK2, PRK2, RSK1, DYRK1a and AMPKα1, selectively inhibiting acute myeloid leukemia (AML) cells with significantly lower toxicity to non-malignant cells (EC50 > 30 μM). VS-II-173 weakens the phosphorylation of substrates such as Stat5 (Y694), MDM2 (S166), Bad (S112), and 4E-BP1 (T37/46) by inhibiting Pim kinase-mediated signaling pathways, blocking pro-survival signals in AML cells and inducing apoptosis. VS-II-173 synergistically enhances anti-AML activity when combined with Daunorubicin (HY-13062A). VS-II-173 can be used in AML research, especially for AML with FLT3-ITD mutations and NPM1 mutations [2].
    VS-II-173

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: